Tango Therapeutics, Inc.
TNGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $337,511 | $936,267 | $636,695 | $679,462 |
| - Cash | $69,530 | $66,385 | $59,968 | $142,745 |
| + Debt | $36,493 | $38,920 | $41,131 | $1,503 |
| Enterprise Value | $304,474 | $908,802 | $617,858 | $538,220 |
| Revenue | $42,069 | $36,527 | $24,860 | $37,042 |
| % Growth | 15.2% | 46.9% | -32.9% | – |
| Gross Profit | $42,069 | $36,527 | $24,860 | $37,042 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$143,096 | -$111,758 | -$109,463 | -$57,293 |
| % Margin | -340.1% | -306% | -440.3% | -154.7% |
| Net Income | -$130,302 | -$101,744 | -$108,176 | -$58,235 |
| % Margin | -309.7% | -278.5% | -435.1% | -157.2% |
| EPS Diluted | -1.19 | -1.08 | -1.23 | -0.94 |
| % Growth | -10.2% | 12.2% | -30.9% | – |
| Operating Cash Flow | -$131,501 | -$117,982 | -$109,080 | -$59,527 |
| Capital Expenditures | -$754 | -$1,526 | -$7,692 | -$1,837 |
| Free Cash Flow | -$132,255 | -$119,508 | -$116,772 | -$61,364 |